Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

730 Articles

Chris Lange | Dec 28, 2016 at 10:10 AM EST

Biotech Short Interest Sinks

The December 15 short interest data have been compared with the previous report, and short interest was down in most…

Chris Lange | Dec 12, 2016 at 9:10 AM EST

Biotech Short Interest Remains Mixed

The November 30 short interest data have been compared with the previous report, and short interest was mixed in the…

Paul Ausick | Dec 8, 2016 at 4:04 PM EST

FitBit, Gilead Sciences in Thursday’s 52-Week Low Club

December 8, 2016: Here are four stocks trading with relatively heavy volume among 34 equities making new 52-week lows in…

Chris Lange | Nov 28, 2016 at 7:35 AM EST

Short Sellers Grow More Aggressive on Major Biotechs

The November 15 short interest data have been compared with the previous report, and short interest increased in most of…

Jon C. Ogg | Nov 10, 2016 at 1:26 PM EST

Gilead Scores Another Hepatitis FDA Approval

Gilead Sciences has announced that the FDA has approved its once-a-day treatment for adults with chronic hepatitis B virus infection.

Chris Lange | Nov 10, 2016 at 7:20 AM EST

Short Sellers Grow More Selective on Major Biotechs

Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can…

Jon C. Ogg | Nov 6, 2016 at 10:20 AM EST

How Analysts View Value and Opportunity in Gilead After Earnings

If you just looked at formal Buy and Sell ratings from Wall Street analysts, you might assume that everything is…

Chris Lange | Nov 1, 2016 at 4:58 PM EDT

Has Gilead Finally Bottomed?

Gilead Sciences Inc. (NASDAQ: GILD) released third-quarter earnings report after markets closed on Tuesday. Despite negative news coming out on…

Chris Lange | Nov 1, 2016 at 11:15 AM EDT

What to Expect From Gilead Earnings

Although Gilead has been falling for about a year now, the valuation is looking more favorable — assuming Gilead is…

Chris Lange | Oct 30, 2016 at 10:05 AM EDT

8 Top Earnings for the Week Ahead

24/7 Wall St. has put together a preview of Pfizer, Starbucks and some of the major companies reporting their quarterly…

Chris Lange | Oct 26, 2016 at 7:15 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The October 14 short interest data have been compared with the previous report, and short interest moves in these selected…

Jon C. Ogg | Oct 20, 2016 at 12:25 PM EDT

How Just 10 States Saved Almost $120 Billion in 2015 Using Generic Drugs

Americans generally would like to spend less money on health care. One way that this can be and will be…

Lee Jackson | Oct 20, 2016 at 9:55 AM EDT

Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains

These top biotech companies have been absolutely hammered and now trade at a valuation much lower than large cap pharmaceuticals.

Paul Ausick | Oct 13, 2016 at 4:04 PM EDT

Ericsson, Nokia Stumble into Thursday’s 52-Week Low Club

October 13, 2016: Here are four stocks trading with relatively heavy volume among 80 equities making new 52-week lows in…

Paul Ausick | Oct 12, 2016 at 4:04 PM EDT

Ericsson, Gilead Tumble Into Wednesday’s 52-Week Low Club

October 12, 2016: Here are four stocks trading with relatively heavy volume among 52 equities making new 52-week lows in…

1 … 22 23 24 25 26 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Biotech Short Interest Sinks

Biotech Short Interest Remains Mixed

FitBit, Gilead Sciences in Thursday’s 52-Week Low Club

Short Sellers Grow More Aggressive on Major Biotechs

Gilead Scores Another Hepatitis FDA Approval

Short Sellers Grow More Selective on Major Biotechs

How Analysts View Value and Opportunity in Gilead After Earnings

Has Gilead Finally Bottomed?

What to Expect From Gilead Earnings

8 Top Earnings for the Week Ahead

Short Sellers Can’t Make Up Their Minds on Major Biotechs

How Just 10 States Saved Almost $120 Billion in 2015 Using Generic Drugs

Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains

Ericsson, Nokia Stumble into Thursday’s 52-Week Low Club

Ericsson, Gilead Tumble Into Wednesday’s 52-Week Low Club

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Gilead Sciences : GILD

All Gilead Sciences Articles

Biotech Short Interest Sinks

Biotech Short Interest Remains Mixed

FitBit, Gilead Sciences in Thursday’s 52-Week Low Club

Short Sellers Grow More Aggressive on Major Biotechs

Gilead Scores Another Hepatitis FDA Approval

Short Sellers Grow More Selective on Major Biotechs

How Analysts View Value and Opportunity in Gilead After Earnings

Has Gilead Finally Bottomed?

What to Expect From Gilead Earnings

8 Top Earnings for the Week Ahead

Short Sellers Can’t Make Up Their Minds on Major Biotechs

How Just 10 States Saved Almost $120 Billion in 2015 Using Generic Drugs

Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains

Ericsson, Nokia Stumble into Thursday’s 52-Week Low Club

Ericsson, Gilead Tumble Into Wednesday’s 52-Week Low Club

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%